{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"invariant_mode_decomposition_design__medicine_healthcare","archetype_slug":"invariant_mode_decomposition_design","domain_slug":"medicine_healthcare","title":"Coupled-physiology mode trigger for earlier ward deterioration review","opportunity_summary":"Test whether reproducible, weakly damped joint trajectories in ward vital signs and laboratory data can request useful clinician review before existing thresholds fire. The proposal is bounded and falsifiable, but the coupled pattern, comparative warning advantage, portability, demand, and distinctiveness remain unestablished.","adopter_authorizer":"Clinical governance, privacy oversight, responsible adult-ward leadership, and health-data leadership would authorize data use and workflow testing; licensed clinicians retain patient-care authority.","scores":{"meaningful_impact":{"score":4,"rationale":"Earlier recognition could reduce progression to emergency escalation, ICU transfer, or other serious harm, but the frequency of missed reversible deterioration and realized clinical benefit are unsupported hypotheses."},"stakeholder_pull":{"score":3,"rationale":"Patients, ward clinicians, rapid-response services, and governance teams have identifiable stakes in timely review and alert burden, but the packet contains no evidence of expressed demand, procurement interest, or workflow acceptance."},"incremental_advantage":{"score":3,"rationale":"The modal trigger offers a testable possibility of greater lead time and traceable contributing measurements, yet no advantage has been observed over usual monitoring or the matched nonlinear rival."},"distinctiveness_plausibility":{"score":2,"rationale":"Invariant-mode structure and modal traceability provide a specific framing, but prior art is explicitly unsearched and related dynamic latent-state, spectral, and longitudinal warning approaches may already cover the claim."},"technical_implementability":{"score":3,"rationale":"A retrospective model and silent shadow test are technically bounded, but treatment confounding, informative sampling, missingness, nonstationarity, ill-conditioned or unstable modes, and clinical-data integration create substantial execution risk."},"adoption_authority_feasibility":{"score":4,"rationale":"The packet identifies governance, privacy, ward, and clinical authorities, preserves licensed-clinician control, and specifies a silent first test; actual approvals and partner commitment are not established."},"evidence_readiness":{"score":4,"rationale":"The candidate specifies baselines, a matched rival, held-out validation, fixed-alert-burden utility, subgroup and stability checks, falsifiers, halt criteria, and a silent test, although dataset access and quantitative pass criteria are not supplied."},"safety_net_benefit":{"score":4,"rationale":"The proposed evidence sequence leaves existing alerts and care unchanged, produces no visible alerts initially, prohibits autonomous care decisions, and has explicit halt and rollback rules; privacy and false-reassurance risks still require controls."},"scalability":{"score":2,"rationale":"The same analytic pattern could in principle extend across wards, but unit, treatment-regime, sampling, pipeline, and temporal variation may destabilize modes and require local validation and governance at each site."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"Locked retrospective validation on an existing longitudinal adult-ward dataset, including cohort construction, baseline and rival implementation, modal analysis, subgroup checks, and evaluation.","confidence":"LOW","assumptions":["A partner already holds sufficiently complete and linkable ward data.","The estimate includes clinical, data-science, engineering, governance, privacy, and evaluation labor.","No new bedside equipment or prospective data collection is required.","Data-access remediation could move the work into a higher band."]},"initial_deployment_startup":{"band_2026_usd":"50K_TO_250K","scope":"One-ward, eight-week silent shadow test with locked model deployment, data-pipeline integration, monitoring, privacy controls, incident response, and prospective evaluation.","confidence":"LOW","assumptions":["Retrospective criteria have passed before startup.","The hospital has usable streaming or frequently refreshed vital-sign and laboratory feeds.","No clinician-visible interface, paging integration, or care-pathway change is included.","Institutional security and privacy review can reuse existing infrastructure."]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"Limited clinician-visible launch at one institution after successful silent testing, including workflow design, interface and alert integration, training, validation, governance approval, safety monitoring, and rollback capability.","confidence":"LOW","assumptions":["Launch remains review-only and does not authorize diagnosis or treatment.","Existing monitoring and escalation workflows remain active.","The model requires institution-specific calibration and subgroup verification.","A broader multi-site deployment would likely require a higher band."]},"annual_recurring":{"band_2026_usd":"250K_TO_1M","scope":"Annual operation at one institution, including data-pipeline support, drift and residual monitoring, periodic revalidation, subgroup surveillance, clinical governance, privacy compliance, incident response, and user support.","confidence":"LOW","assumptions":["Continuous monitoring is necessary because modes may vary across time and treatment regimes.","Material model changes trigger renewed silent validation.","Costs exclude downstream staffing increases caused by an unproven alert burden.","Existing hospital compute and data platforms are available."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"YES","reason":"The sealed candidate identifies delayed recognition of ward deterioration despite existing monitoring as a clinically consequential problem independent of the modal mechanism, while leaving its prevalence uncertain."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"Clinical governance, privacy oversight, ward leadership, health-data teams, and licensed clinicians have explicit authorization or care-authority roles."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The trigger claims improved lead time and sensitivity at a fixed alert burden over both usual monitoring and a calibrated nonlinear model using the same inputs."},"bounded_next_evidence_step":{"status":"YES","reason":"A locked retrospective comparison with residual, stability, subgroup, temporal, unit, and treatment-regime checks is specified before any eight-week silent shadow test."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The authorized sequence is non-interventional and silent, retains existing alerts and clinician authority, excludes autonomous care actions, and specifies privacy, performance, and pipeline halt conditions."},"implementation_cost_scope_and_range":{"status":"UNCERTAIN","reason":"The candidate bounds retrospective, silent, and later workflow phases, but data readiness, integration complexity, approval effort, staffing, and alert-generated workload are unknown, so the broad resource bands remain low-confidence."}},"blocking_evidence":["Whether held-out deterioration cases contain reproducible coupled temporal structure beyond treatment and measurement artifacts.","Whether the modal trigger improves lead time and sensitivity at a fixed alert burden over both usual monitoring and the matched nonlinear rival.","Whether modes, thresholds, residual behavior, and interpretations remain stable across time, wards, treatment regimes, sampling patterns, and relevant subgroups.","Whether retrospective data access, data quality, outcome definitions, and privacy authorization are adequate for a locked evaluation.","Whether prior approaches already provide materially equivalent dynamic structure or traceability.","Whether a later visible trigger would create acceptable alert burden and workflow displacement."],"next_evidence_step":"With an authorized hospital partner, preregister and run a locked retrospective held-out comparison of the modal trigger, usual monitoring, and a calibrated nonlinear rival using identical longitudinal inputs. Measure lead time and sensitivity at fixed alert burden, calibration, residual structure, modal conditioning and gap stability, and temporal, ward, treatment-regime, missingness, and subgroup robustness. Falsify advancement if coupled structure is not reproducible, either comparator matches or exceeds warning utility, residuals remain outcome-relevant, modes are unstable or ill-conditioned, or subgroup criteria fail; proceed to the silent eight-week test only after all prespecified criteria pass.","research_questions":["Does impending deterioration exhibit repeatable coupled temporal structure after accounting for treatments, observation intensity, missingness, and ordinary thresholds?","Does modal structure add warning utility over a calibrated nonlinear model trained on the same information?","What spectral separation, conditioning, persistence, residual, and interpretation-window criteria are required for a safe trigger?","How stable are learned modes and locked thresholds across wards, calendar periods, treatment regimes, and patient subgroups?","What alert burden and lead-time tradeoff would ward and rapid-response leaders consider clinically useful?","What data access, pipeline, privacy, governance, and staffing resources are required for silent and visible operation?","Do existing dynamic latent-state, switching-system, spectral, or longitudinal deterioration-warning methods anticipate the proposed incremental claim?"] ,"recommendation":"PARTNERED_RESEARCH","uncertainty_constraints":["Closed-book assessment provides no evidence of problem prevalence, stakeholder demand, comparative performance, novelty, market size, or realized patient benefit.","All cost bands are resource-equivalent planning ranges rather than quotes and depend heavily on partner data and infrastructure readiness.","The proposed modal coordinates cannot be treated as biological causes.","The 3-to-12-month horizon applies only to first comparative evidence and a possible silent test, not proven clinical benefit or scaled adoption.","Any clinician-visible test requires new evidence and authorization beyond the sealed first step."],"closed_book_prior_art_boundary":"Prior art is explicitly unsearched. This assessment makes no claim that invariant-mode deterioration detection, modal traceability, or the proposed trigger is novel, rare, prevalent, or commercially distinct; documented external research is required before any distinctiveness claim."}